每经头条（nbdtoutiao）——与美元脱钩后，暴涨102倍，揭秘黄金疯涨背后神秘的"无形之手"！专家： 推动金价上涨的逻辑没有变 （记者 王瀚黎） 2024年1至12月份，诺唯赞的营业收入构成为：研究和试验发展占比85.17%，医药制造业占比14.66%， 其他业务占比0.17%。 截至发稿，诺唯赞市值为92亿元。 每经AI快讯，诺唯赞（SH 688105，收盘价：23.1元）10月9日晚间发布公告称，截至2025年9月30日， 公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份4万股，占公司总股本约3.98 亿股的比例为0.01%，回购成交的最高价为24.26元/股，最低价为24.36元/股，支付的资金总额为人民币 约97万元。 ...

Market Overview - After the National Day holiday, A-shares resumed trading, and southbound funds returned, with Hong Kong's three major indices showing mixed results. The Hang Seng Index fell by 0.29% to 26,752.59 points, with a total turnover of HKD 38.68 billion [1] - CITIC Securities believes that the Hong Kong market benefits from a complete domestic AI industry chain and the increasing number of quality A-share companies listing in Hong Kong. The firm expects the long bull market that began in early 2024 to continue despite short-term geopolitical and trade uncertainties [1] Blue Chip Performance - HSBC Holdings led blue-chip stocks, rising by 25.88% to HKD 149.8, contributing 36.11 points to the Hang Seng Index. HSBC announced plans to privatize Hang Seng Bank at a price of HKD 155 per share, a 30% premium over the previous closing price [2] - Other notable blue-chip movements included Lenovo Group up 7.26%, Zijin Mining up 5.43%, while China Biologic Products fell by 7.49% and SMIC dropped by 6.7% [2] Sector Highlights - Large technology stocks showed mixed results, with Kuaishou rising over 3% and Alibaba falling over 2%. Precious metals saw significant gains during the holiday, with gold, silver, copper, and aluminum prices rising sharply [3][4] - The AI sector experienced varied performance, with Lenovo and Bilibili seeing gains, while Alibaba faced a decline. The recent acceleration in AI investments and applications is expected to strengthen the narrative around the sector [4][5] Notable Stocks - Shanghai Electric surged by 17.4% after achieving a key breakthrough in nuclear fusion technology, positioning itself as a leader in this field [7] - Goldwind Technology rose by 8.43%, benefiting from its role in promoting green energy transitions [8] - Jinli Permanent Magnet reached a new high, increasing by 8.67%, following announcements of export controls on rare earth-related items by the Ministry of Commerce [9] - HSBC Holdings faced pressure, dropping by 5.97%, amid its announcement regarding the privatization of Hang Seng Bank [10]

德州市医药及康养产业链办公室主任、市卫生健康委员会党组书记、主任周春华表示，德州市将以 《德州市医养健康产业发展规划（2024—2027）》为指引，聚焦"医、药、养、中、融"五大重点，深 化"北接南融"策略，完善"一极引领、三带协同、五地支撑、全域联动"产业布局，推动产业实现更高质 量发展。 德州全域联动推动医药及康养产业高质量发展 打造产业高地 推动跨界融合 德州市围绕医药制造、医疗器械、医疗服务和康养服务等四大领域，通过"链长统筹、链办协调、 部门联动、属地落实"工作机制，推动医药及康养产业实现跨越式发展，并致力打造在全国有影响力的 产业高地。截至2024年，产业链已聚集规上企业及机构108家，营收达180.26亿元。 打破产业边界，推动医药制造、医疗服务与康养、文旅深度融合，是德州医药及康养产业的一大亮 点。在医养结合领域，11个县（市、区）全部入选省级医养结合示范先行县，106个镇街获评省级医养 结合示范乡镇；建成医养结合机构85家，床位达1.7万张，1005家医疗机构可提供居家上门服务。德州 市医养健康集团有限公司突出养老服务、健康管理、中医药产业以及发展新动能，建设德州养老示范 城、德州市康养中心 ...

10月9日早盘，恒指高开0.12%，恒生科技指数涨0.41%。 医药股持续升温，诺诚健华涨近3%，与Zenas达成逾20亿美元授权协议；科网股延续活跃表现，蔚来涨 近2%；黄金等有色行业小幅回撤，赤峰黄金跌逾3%。 恒生银行跳空大涨15%，汇丰拟将恒生银行私有化，交易价值约2907亿港元。 | મટા | 恒生指数 | ww | 26862.03 | 32.57 | 0.12% | | --- | --- | --- | --- | --- | --- | | HSTECH | 恒生科技 | Inv | 6540.81 c | 26.62 | 0.41% | ...

目前，德州市鱼油及制品、头孢米诺钠两种产品在全球市场占有率位居第一，咖啡酸片等8种产品 在全国市场占有率稳居第一。山东百多安医疗器械股份有限公司研发的"经外周中心静脉导管产品"和山 东安颂和德医疗科技有限公司研发的"人工陶瓷髋关节假体"攻克了关键性技术，实现高端医疗器械国产 化。在产业链延伸方面，卡森细胞等29家行业领军企业及齐鲁制药、上海医药集团、修正药业等龙头企 业在德州市布局生产基地，并联动中关村海淀园共建生命科学城，产业链条不断完善。 医养健康产业直接关系民生福祉。德州市构建优质高效的医疗卫生服务体系，让群众在家门口就能 享受到高水平医疗服务。德州市成立京德医疗健康事业促进委员会，累计达成"北京名中医工作站"等合 作成果150余项；通过"卫生英才"和"大德名医"等工程，培育省级以上高层次人才118名，引进高学历、 高职称人才超2000名，为医疗服务水平提升提供了人才保障。 眼下，齐河县，山东卡森细胞治疗工程技术有限公司（以下简称卡森细胞）实验室内，正在进行攻 坚肿瘤免疫治疗技术的研究。"目前，我们联合山东大学专家团队正在开展针对乳腺癌、肝癌和肺癌等 实体瘤的TCR-T细胞治疗技术攻关项目，构建符合国际 ...

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index dropping 0.48% to close at 26,829.46 points, while the total trading volume reached 173.8 billion HKD [1] - The market is expected to enter a "low season" due to the impact of the National Day and Mid-Autumn Festival holidays, compounded by uncertainties surrounding the U.S. government's short-term financing plan [1] Blue-Chip Stocks Performance - Geely Automobile (00175) saw a notable increase of 3.36%, closing at 19.67 HKD, contributing 6.07 points to the Hang Seng Index. The company announced a share buyback plan worth up to 2.3 billion HKD, indicating management's belief that the stock is undervalued [2] - Other blue-chip stocks included Hengan International (01044) up 3.46%, NetEase-S (09999) up 2.92%, while Semiconductor Manufacturing International Corporation (00981) and CNOOC (00883) saw declines of 1.7% and 1.39%, respectively [2] Sector Performance Gold Stocks - Gold stocks performed strongly, with several companies reaching new highs. Chifeng Jilong Gold Mining (06693) rose 13.26%, China Silver Group (00815) increased by 12.5%, and Shandong Gold (01787) was up 7.61% [3] - Spot gold prices surpassed 4,000 USD per ounce, marking a year-to-date increase of nearly 1,400 USD per ounce, or over 52% [3] Cryptocurrency Stocks - Cryptocurrency-related stocks faced declines, with Boyaa Interactive (00434) down 8.48% and Okcoin Chain (01499) down 7.69%. The drop in Bitcoin futures contributed to the negative sentiment in this sector [4] Cloud Computing Stocks - Cloud computing stocks were negatively impacted by disappointing profit margins reported by Oracle's cloud business, with Mingyuan Cloud (00909) down 4.92% and Alibaba-W (09988) down 1.61% [4][5] Notable Stock Movements - Changfeng Pharmaceutical (02652) debuted with a significant increase of 161.02%, closing at 38.5 HKD, following a successful IPO [7] - Xinjiang Xin Mining (03833) continued its upward trend, closing up 16.88% at 3.6 HKD, driven by plans to issue A-shares [7] Industry Developments - The U.S. government is actively working to rebuild its rare earth industry, with discussions to invest in Critical Metals, which could provide direct ownership of Greenland's largest rare earth project [8] - Jiangxi Copper (00358) reached a new high, closing up 6.02% at 35.2 HKD, amid expectations of a copper supply shortage due to the Grasberg mine's shutdown [9]

Core Insights - Nanjing Biomedicine Valley has introduced over 50 innovative products and technologies that are first in the world or country, highlighting its role as a key player in the biomedicine industry [1] - The region is focusing on precision medicine and niche areas such as brain science and gene therapy, aiming to establish a comprehensive innovation ecosystem [2][3] - Two new class 1 drugs have been approved this year, marking a significant achievement for the Nanjing Biomedicine Valley [3][4] Industry Overview - The global biomedicine industry is accelerating towards precision diagnosis and treatment, with Nanjing Biomedicine Valley positioning itself in niche markets [2] - The region has established a full industrial chain in gene and cell therapy, including gene testing, diagnostics, and CAR-T cell therapy [3] - The Nanjing Biomedicine Valley has attracted over 1,300 companies, with 7 companies successfully listed and 6 class 1 drugs approved [5] Innovation and Development - The Nanjing Biomedicine Valley is enhancing its innovation capabilities by collaborating with universities and establishing technology transfer centers [6] - A total of 84 billion yuan fund support plan has been launched to facilitate the transformation of scientific achievements from universities [6] - The region is focusing on building a robust innovation ecosystem that integrates innovation chains, industry chains, capital chains, and talent chains [7] Recent Achievements - The approval of two class 1 drugs, Enze Shou and Ji Ke Shu, represents a milestone for the biomedicine valley, with the former being the first targeted drug for platinum-resistant ovarian cancer in China [3][4] - The establishment of the Jiangsu Brain Intelligence Technology Innovation Center aims to make breakthroughs in brain science over the next five years [2] - The Nanjing Biomedicine Valley has successfully facilitated the listing of companies and the approval of innovative drugs, showcasing its supportive environment for biomedicine enterprises [5][6]

白云山为何要入股南京医药？除了通过受让股权成为南京医药第二大股东外，白云山还与南京医药签署 了战略投资协议，双方积极制定市场拓展与渠道共享方案，整合优化供应链资源和物流配送网络，建立 稳定、高效的供应链体系等，实现协同发展。 入股地处江苏的南京医药，白云山将加码布局华东市场。 受近年来政策及市场变化等多种因素影响，白云山的经营业绩也出现了小幅调整。入股南京医药，白云 山谋求突围。 战投南京医药（600713.SH），广药集团旗下的白云山（600332.SH）将间接成为南京医药的第二大股 东。 近期，白云山及南京医药均公告，2025年9月26日，白云山附属企业广州广药二期基金股权投资合伙企 业（有限合伙）（简称"广药二期基金"）与相关方签署协议，拟受让南京医药11.04%的股权，交易价款 约7.49亿元。 长江商报消息 ●长江商报记者 沈右荣 分析人士认为，无论是医药制造还是医药流通环节，市场竞争加剧，"野蛮生长"时代已经过去，通过股 权纽带，寻求协同发展或将是突围之道。 携7.49亿入股南京医药 通过受让股权，白云山成了南京医药间接第二大股东。 2025年9月28日，白云山发布公告，公司附属企业广药二期基金与 ...

2019年-2025年1-8月全国医药制造业出口货值统计图 数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 上市公司：国药现代（600420），昆药集团（600422），片仔癀（600436），千金药业（600479），津 药药业（600488），国药股份（600511），联环药业（600513），合富中国（603122），康惠制药 （603139），莎普爱思（603168），奥翔药业（603229），大参林（603233） 相关报告：智研咨询发布的《2025-2031年中国医药制造行业市场发展态势及前景战略研判报告》 根据国家统计局数据可知：2025年8月全国医药制造业出口货值为194.2亿元，同比增长16.2%；2025年 1-8月全国医药制造业累计出口货值为1536.8亿元，累计同比增长11.6%。 ...

智通财经APP获悉，港股10月迎开门红，三大指数全天震荡走强，恒指再度突破两万七大关，恒科指则 大涨超3%，均创近四年新高。截止收盘，恒生指数涨1.61%或431.56点，报27287.12点，全日成交额为 2224.68亿港元；恒生国企指数涨1.77%，报9724.38点；恒生科技指数涨3.36%，报6682.86点。 交银国际认为，港股"慢牛"行情有望持续演绎。9月港股延续震荡上行态势，在中美谈判重启和海外降 息预期双重利好助推下，叠加科技板块轮动上涨，对大盘形成重要提振。此外，海外降息重启，中国香 港流动性压力缓解，南向资金延续加速涌入。该行建议关注美联储降息节奏、中美关系进展及中国内地 稳增长政策兑现情况。 蓝筹股表现 中芯国际(00981)再创新高，截至收盘，涨12.7%，报89.65港元，成交额58.41亿港元，贡献恒指71.26 点。高盛研报指出，尽管消费电子及智能手机贡献66%收入，该行对中芯国际中长期订单扩张持乐观态 度，受惠下游客户市占增长及电子设备中半导体含量升级，特别是人工智能功能加速部署。该行维持对 中芯"买入"评级，上调估值基础，由预测2028年市盈率45.2倍升至51.1倍，H股 ...